Physician profile
Farrel Douglas
NPI 1497757561
$19,843.42
in general payments reported to CMS, 2019-2025
64 companies · $4,501 in 2025
The $4,501 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,396 · 2020: $883 · 2021: $1,143 · 2022: $2,612 · 2023: $3,981 · 2024: $3,326 · 2025: $4,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $150 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,542.51 |
| Consulting Fee | $150.00 |
| Education | $116.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,464.42 | 2019-2025 | Mavenclad |
| Abbvie INC. | $1,452.98 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Ucb, INC. | $1,421.52 | 2019-2025 | Fintepla, Zilbrysq, Briviact |
| Mdd US Operations, LLC | $1,344.78 | 2019-2025 | Gocovri, Apokyn, Gocovri |
| Teva Pharmaceuticals USA, INC. | $1,100.24 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $1,035.63 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Novartis Pharmaceuticals Corporation | $950.04 | 2019-2025 | |
| Sk Life Science, INC. | $912.52 | 2020-2025 | Xcopri |
| Pfizer INC. | $791.27 | 2019-2025 | |
| Lilly USA, LLC | $615.56 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Csl Behring | $568.99 | 2019-2025 | Hizentra |
| Supernus Pharmaceuticals, INC. | $509.54 | 2019-2025 | Qelbree |
| Alexion Pharmaceuticals, INC. | $421.70 | 2019-2025 | Ultomiris |
| Celgene Corporation | $401.65 | 2021-2025 | Zeposia |
| Eisai INC. | $386.13 | 2019-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farrel Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.